Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)

NCT07353437 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07353437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07353437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2026
Completion date
December 31, 2032
Enrollment
334 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer